Comment · Tue, March 31, 2015 · Ceretropic
Tianeptine Sulfate is VASTLY SUPERIOR to Tianeptine Sodium
Original post in this thread
Gorthaur111 · 46 points
I have been using the new Tianeptine Sulfate for five days now, and it just blows away Tianeptine Sodium. The timed release effect works perfectly - a single dose lasts at least six hours, if not ten. There are no highs and lows in mood. There's no strong euphoria, and more importantly, there's no crash either.
I have been using tianeptine as my primary antidepressant since last June. For several months, I've been taking about 100 mg a day. The need to redose every 2-3 hours has been frustrating and impractical, so the ability to go for most of the day on one dose makes tianeptine so much more valuable. I find that a single 100 mg dose of tianeptine sulfate kicks in within 15 minutes, hits peak effect from 1-3 hours in, and hangs on for many more hours. It might be able to last all day, but I find myself taking a booster of tianeptine sodium in the evening, just out of habit.
Since the changes in blood concentration of tianeptine sulfate are more gradual, it is clearly much less addictive than the sodium form. (The faster a drug kicks in, and the steeper the spike in dopamine, the more addictive it is.) If and when I need to stop taking tianeptine, the sulfate form will make a…
What they were answering
EternalOptimist829 · 3 points
As someone else brought up this compound has a patent on it already. How does it work that you can produce this without any issue?
u/MisterYouAreSoDumb · Ceretropic
We are taking a calculated risk. The patent holder is a billion dollar company, that is currently not developing the drug, or planning trials. So rather than have it stagnate, and not be used by people that can benefit from it, we might as well get it out there. I doubt the patent holder is going to care about us. We are like single-celled organisms to them. It's not worth their time. If they start putting it through trials, and moving to approve it, then it might change. We'll see.